Chairman and CEO of Abbott Laboratories (NYSE:ABT), recently sold a significant portion of his holdings in the company. According to a Form 4 filing with the Securities and Exchange Commission, Ford ...

The last few weekends have been roiled by headlines. Here's why we took a different direction on this medical stock this week.

The stock's fall snapped a three-day winning streak.

The company reported revenue of $10.97 billion and earnings of $1.34 on a per-share and adjusted basis, compared to the consensus estimates of $11.01 billion and ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

Shares of Abbott Laboratories ABT rose 2.29% to $132.06 Wednesday, on what proved to be an all-around positive trading ...

Piper reiterates the Overweight rating with a price forecast of $133. Price Action: Abbott stock is up 3.7% at $122.15 at last check Thursday.

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Abbott is expected to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...